IB-Stim
Functional Abdominal Pain associated with IBS & Functional Dyspepsia (Pediatric/Adolescent)
Key Facts
About NeurAxis
NeurAxis is a commercial-stage medical device company pioneering neuromodulation therapies for disorders of gut-brain interaction (DGBIs), such as functional abdominal pain associated with IBS and functional dyspepsia. Its flagship product, IB-Stim, is an FDA-cleared device that uses percutaneous electrical nerve field stimulation (PENFS) applied behind the ear, representing a first-to-market, non-pharmacologic treatment option primarily for the pediatric and adolescent population. The company is actively expanding market access through insurance coverage policies and has recently secured significant FDA label expansions into adult populations. Financially, it is revenue-generating with strong growth, supported by strategic financing and a public listing.
View full company profileAbout NeurAxis
NeurAxis is a commercial-stage medical device company pioneering neuromodulation therapies for disorders of gut-brain interaction (DGBIs), such as functional abdominal pain associated with IBS and functional dyspepsia. Its flagship product, IB-Stim, is an FDA-cleared device that uses percutaneous electrical nerve field stimulation (PENFS) applied behind the ear, representing a first-to-market, non-pharmacologic treatment option primarily for the pediatric and adolescent population. The company is actively expanding market access through insurance coverage policies and has recently secured significant FDA label expansions into adult populations. Financially, it is revenue-generating with strong growth, supported by strategic financing and a public listing.
View full company profileAbout NeurAxis
NeurAxis is a commercial-stage medical device company pioneering neuromodulation therapies for disorders of gut-brain interaction (DGBIs), such as functional abdominal pain associated with IBS and functional dyspepsia. Its flagship product, IB-Stim, is an FDA-cleared device that uses percutaneous electrical nerve field stimulation (PENFS) applied behind the ear, representing a first-to-market, non-pharmacologic treatment option primarily for the pediatric and adolescent population. The company is actively expanding market access through insurance coverage policies and has recently secured significant FDA label expansions into adult populations. Financially, it is revenue-generating with strong growth, supported by strategic financing and a public listing.
View full company profile